How is Doxil metabolized?
How is Doxil metabolized?
The currently known metabolism of doxorubicin is mainly mediated by the cytochrome P450. in addition, carbonyl reductase and aldo-keto reductase have also been shown to be involved in some metabolic processes.
What is pegylated liposomal?
Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers.
Is Doxil pegylated?
Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile.
How does doxorubicin affect cell cycle?
DOX treatment resulted in significant cellular morphological alteration with increased intracellular granularity and cell size. DOX inhibited cell proliferation through cell cycle arrest at the G(2)/M phase as well as by cell death.
What is the purpose of doxorubicin?
Doxorubicin is used in combination with other medications to treat certain types of bladder, breast, lung, stomach, and ovarian cancer; Hodgkin’s lymphoma (Hodgkin’s disease) and non-Hodgkin’s lymphoma (cancer that begins in the cells of the immune system); and certain types of leukemia (cancer of the white blood cells …
How is doxorubicin excreted?
Excretion: Excreted primarily in bile. A minute amount is eliminated in urine. The plasma elimination of doxorubicin is described as biphasic with a half-life of about 15 to 30 minutes in the initial phase and 16 1/2 hours in the terminal phase.
Is doxorubicin hydrophilic or hydrophobic?
Hydrophilic doxorubicin hydrochloride (DOX·HCl) or hydrophobic doxorubicin base (DOX) were encapsulated into these polymersomes with high payload and high encapsulation efficiency due to the strong intermolecular interaction with polyphosphazene chain [529].
What is PEGylation of proteins?
PEGylation is a biochemical modification process of bioactive molecules with polyethylene glycol (PEG), which lends several desirable properties to proteins/peptides, antibodies, and vesicles considered to be used for therapy or genetic modification of cells.
How is Caelyx given?
CAELYX is administered intravenously at a dose of 50 mg/m2 once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
What is the purpose of PEGylation?
In general, PEGylation improves drug solubility and decreases immunogenicity. PEGylation also increases drug stability and the retention time of the conjugates in blood, and reduces proteolysis and renal excretion, thereby allowing a reduced dosing frequency.
What is the difference between Doxil and doxorubicin?
Doxil is the trade name for doxorubicin liposomal. In some cases, health care professionals may use the trade name doxil when referring to the generic drug name doxorubicin liposomal. Drug type: Doxorubicin (liposomal) is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
Which is liposomal formulation of doxorubicin is pegylated?
Pegylated liposomal doxorubicin (doxorubicin HCl liposome injection; Doxil or Caelyx) is a liposomal formulation of doxorubicin, reducing uptake by the reticulo-endothelial system due to the attachment of polyethylene glycol polymers to a lipid anchor and stably retaining drug as a result of liposom …
How is doxorubicin pegylated in stealth stealth liposomes?
Pegylated liposomal doxorubicin (PLD) is a formulation of doxorubicin in polyethylene glycol (PEG) coated Stealth® liposomes. 3 “Pegylation” is the process whereby the doxorubicin-containing liposomes are enclosed within a PEG layer.
How is doxorubicin metamorphosis into a new form of chemotherapy?
Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy Pegylated liposomal doxorubicin (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with a prolonged circulation time and unique toxicity profile.
What is the pharmacokinetic profile of doxorubicin in humans?
The pharmacokinetic profile in humans at doses between 10 and 80 mg/m(2) is similar to that in animals, with one or two distribution phases: an initial phase with a half-life of 1-3 hours and a second phase with a half-life of 30-90 hours. The AUC after a dose of 50 mg/m(2) is approximately 300-fold greater than that with free drug.
